Evidence map›Paper›PMID 40606916›Full record

ArticleWorld journal of hepatology2025

Relationship between glucagon and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus.

Yi Sun, Ping Huang, Xiao-Qin Zhao, Zhu-Qi Tang, Tong-Tong Xu, Xin-Wei Wang, Zong-Xian Qi, Wei-Rong Lin, Min-You Li, Yun-Juan Gu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi SunDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China.
Ping HuangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China.
Xiao-Qin ZhaoDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China.
Zhu-Qi TangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China.
Tong-Tong XuDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China.
Xin-Wei WangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China.
Zong-Xian QiR&D Department, Guangzhou Jinde Biotech Company Limited, Guangzhou 510000, Guangdong Province, China.
Wei-Rong LinR&D Department, Guangzhou Jinde Biotech Company Limited, Guangzhou 510000, Guangdong Province, China.
Min-You LiR&D Department, Guangzhou Jinde Biotech Company Limited, Guangzhou 510000, Guangdong Province, China.
Yun-Juan GuDepartment of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226000, Jiangsu Province, China. desette@ntu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlucagon (GCG) plays an important role in both diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD).

aimTo investigate the relationship between GCG and the development of MASLD in patients with type 2 diabetes mellitus (T2DM) and the possible influencing factors.

methodsA total of 212 T2DM patients were enrolled. GCG concentrations were measured using the chemiluminescence method. Fibro touch ultra sound attention parameter was used to determine the occurrence of MASLD. Multivariate logistic regression analyses were employed to assess the correlation between GCG levels and MASLD severity in T2DM patients.

resultsThe ultrasound attenuation parameter of T2DM patients was positively correlated with GCG, insulin (INS), C-peptide (CP), INS resistance, obesity related indicators (body mass index, waist circumference, percent body fat, basal metabolic rate, visceral fat area, fat free mass index, fat mass index, skeletal muscle index), liver cirrhosis related indicators [liver stiffness measurement (LSM), gamma glutamyl transpeptidase to platelet ratio, alanine aminotransferase], serum uric acid, diastolic blood pressure and triglyceride, while were negative correlated with age, fibrosis 4 score and high-density lipoprotein cholesterol (all

conclusionFasting GCG, fasting CP and LSM are risk factors for MASLD in T2DM patients.

Indexed as

GlucagonLiver stiffness measurementMetabolic dysfunction-associated steatotic liver diseaseType 2 diabetes mellitusUltrasound attenuation parameter

Identifiers

PMID40606916
PMCPMC12210176

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.